Recent therapeutic advances in oncology have been driven by the identification of tumour genotype variations between patients, called interpatient heterogeneity, that predict the response of patients to targeted treatments. Subpopulations of cancer cells with unique genomes in the same patient may exist across different geographical regions of a tumour or evolve over time, called intratumour heterogeneity. Sequencing technologies can be used to characterize intratumour heterogeneity at diagnosis, monitor clonal dynamics during treatment and identify the emergence of clinical resistance during disease progression. Genetic interpatient and intratumour heterogeneity can pose challenges for the design of clinical trials that use these data.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Tran, B. et al. Cancer genomics: technology, discovery, and translation. J. Clin. Oncol. 30, 647–660 (2012).
Mok, T. S. et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).
De Roock, W. et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19, 508–515 (2008).
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).
Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23–28 (1976).
Amir, E. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 30, 587–592 (2012).
Gong, Y., Han, E. Y., Guo, M., Pusztai, L. & Sneige, N. Stability of estrogen receptor status in breast carcinoma. Cancer 117, 705–713 (2011).
Thompson, A. M. et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 12, R92 (2010).
Chang, H. J. et al. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn. J. Clin. Oncol. 41, 593–599 (2011).
Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771–784 (2011).
Lindström, L. S. et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J. Clin. Oncol. 30, 2601–2608 (2012).
Liedtke, C. et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann. Oncol. 20, 1953–1958 (2009).
Tapia, C. et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res. 9, R31 (2007).
Artale, S. et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin. Oncol. 26, 4217–4219 (2008).
Kalikaki, A. et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br. J. Cancer 99, 923–929 (2008).
Kim, H. et al. Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases. Histopathology 62, 305–314 (2013).
Weller, M. et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev. Neurol. 6, 39–51 (2010).
Bozzetti, C. et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br. J. Cancer 104, 1372–1376 (2011).
Kim, M. A., Lee, H. J., Yang, H. K., Bang, Y. J. & Kim, W. H. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 59, 822–831 (2011).
Knijn, N. et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br. J. Cancer 104, 1020–1026 (2011).
Yancovitz, M. et al. Intra-and inter-tumor heterogeneity of BRAFV600E mutations in primary and metastatic melanoma. PLoS ONE 7, e29336 (2012).
Niikura, N. et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J. Clin. Oncol. 30, 593–599 (2012).
Fidler, I. J. & Hart, I. R. Biological diversity in metastatic neoplasms: origins and implications. Science 217, 998–1003 (1982).
Starczynski, J. et al. HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am. J. Clin. Pathol. 137, 595–605 (2012).
Yoon, H. H. et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J. Clin. Oncol. 30, 3932–3938 (2012).
Perez, K. et al. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. Exp. Mol. Pathol. 95, 74–82 (2013).
Wilmott, J. S. et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol. Cancer Ther. 11, 2704–2708 (2012).
Taniguchi, K., Okami, J., Kodama, K., Higashiyama, M. & Kato, K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 99, 929–935 (2008).
Sakurada, A., Lara-Guerra, H., Liu, N., Shepherd, F. A. & Tsao, M.-S. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J. Thorac. Oncol. 3, 527–529 (2008).
Rye, I. et al. Intra-tumor heterogeneity as a predictor of therapy response in HER2 positive breast cancer. Cancer Res. 72, (24 suppl.) P3–05–04 (2012).
Tougeron, D. et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann. Oncol. 24, 1267–1273 (2013).
Bai, H. et al. Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS ONE 8, e54170 (2013).
Coons, S. W., Johnson, P. C. & Shapiro, J. R. Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma. Cancer Res. 55, 1569–1577 (1995).
Walter, M. J. et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090–1098 (2012). This study reconstructs the clonal evolution of secondary acute myeloid leukaemia from myelodysplastic syndrome, demonstrating that a single population of myelodysplastic syndrome cells underwent multiple rounds of mutation and selection.
Newburger, D. E. et al. Genome evolution during progression to breast cancer. Genome Res. 23, 1097–1108 (2013).
Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809–813 (2009). This was the first study to demonstrate how genome sequencing can be used to follow the evolution of a solid tumour from early to advanced stage.
Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–1117 (2010).
Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109–1113 (2010). References 39 and 40 describe how genomic instability drives clonal evolution in metastatic pancreatic cancers.
Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999–1005 (2010).
Diaz, L. A. Jr et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537–540 (2012).
Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532–536 (2012). References 42 and 43 demonstrate how KRAS -mutant subclones in colorectal cancer can emerge under the selection pressure of EGFR antibody therapy to confer treatment resistance.
Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395–399 (2012). This study demonstrates wide variety of clonal and mutational composition in 104 primary triple-negative breast cancers.
Aparicio, S. & Caldas, C. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 368, 842–851 (2013).
Buttitta, F. et al. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin. Cancer Res. 19, 691–698 (2013).
Kinde, I. et al. Evaluation of DNA from the papanicolaou test to detect ovarian and endometrial cancers. Sci. Transl. Med. 5, 167ra164 (2013).
Maheswaran, S. et al. Detection of Mutations in EGFR in Circulating Lung-Cancer Cells. N. Engl. J. Med. 359, 366–377 (2008).
Leary, R. J. et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 4, 162ra154 (2012).
Chan, K. C. A. et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 59, 211–224 (2013).
Forshew, T. et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 4, 136ra168 (2012).
Dawson, S.-J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199–1209 (2013). References 51 and 52 used targeted sequencing of circulating tumour DNA to monitor tumour dynamics in patients with advanced solid tumours.
Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781–791 (2004).
Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108–112 (2013). This study shows that exome sequencing of circulating tumour DNA can be used to track genomic evolution of metastatic cancers in response to therapy.
Lipson, D. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nature Med. 18, 382–384 (2012).
Beltran, H. et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 63, 920–926 (2013).
Swanton, C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 72, 4875–4882 (2012).
CLIA. Medicare, Medicaid and CLIA programs: regulations implementing the clinical laboratory improvement amendments of 1988. Fed. Regist. 57, 7002–7186 (1992).
Wagle, N. et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2, 82–93 (2012).
Bedard, P. et al. Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). J. Clin. Oncol. 31, 11002 (2013).
Miller, V. et al. Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples. J. Clin. Oncol. 31, 11020 (2013). References 59–61 show that next-generation sequencing technology can be applied to stored formalin-fixed, paraffin-embedded tumour samples in a clinical setting.
Gargis, A. S. et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nature Biotechnol. 30, 1033–1036 (2012).
Tran, B. et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int. J. Cancer 132, 1547–1555 (2013).
Dancey, J. E., Bedard, P. L., Onetto, N. & Hudson, T. J. The genetic basis for cancer treatment decisions. Cell 148, 409–420 (2012).
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28, 3534 (2010).
Barretina, J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012).
Papillon-Cavanagh, S. et al. Comparison and validation of genomic predictors for anticancer drug sensitivity. J. Am. Med. Inform. Assoc. 20, 597–602 (2013).
Begley, C. G. & Ellis, L. M. Drug development: raise standards for preclinical cancer research. Nature 483, 531–533 (2012).
Sleijfer, S., Bogaerts, J. & Siu, L. L. Designing transformative clinical trials in the cancer genome era. J. Clin. Oncol. 31, 1834–1841 (2013).
Dienstmann, R. et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol. Cancer Ther. 11, 2062–2071 (2012).
Tsimberidou, A.-M. et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center Initiative. Clin. Cancer Res. 18, 6373–6383 (2012). This study demonstrates that matching investigational treatment to genotype results in better response and survival.
Rodón, J. et al. Molecular prescreening to select patient population in early clinical trials. Nature Rev. Clin. Oncol. 9, 359–366 (2012).
Hollebecque, A. et al. Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial — interim results. J. Clin. Oncol. 31, 2512 (2013).
Kaplan, R. & Brown, L. MRC FOCUS 4: a New Trial Biomarker-Stratified Phase 2/3 Trial Design http://www.methodologyhubs.mrc.ac.uk/annual_htmr_network_meetings/2013_network_meeting.aspx (Medical Research Council, 2013).
Kim, E. S. et al. The BATTLE Trial: personalizing therapy for lung cancer. Cancer Discov. 1, 44–53 (2011).
Barker, A. D. et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97–100 (2009).
Berry, D. A., Herbst, R. S. & Rubin, E. H. Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: design strategies for personalized therapy trials. Clin. Cancer Res. 18, 638–644 (2012).
Lillie, E. O. et al. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per. Med. 8, 161–173 (2011).
Gabler, N. B., Duan, N., Vohra, S. & Kravitz, R. L. N-of-1 trials in the medical literature: a systematic review. Med. Care 49, 761–768 (2011).
Mick, R., Crowley, J. J. & Carroll, R. J. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control. Clin. Trials 21, 343–359 (2000).
Kurzrock, R. & Tabernero, J. WINTHER — WIN Therapeutics Clinical Trial. http://www.winconsortium.org (WIN Consortium, 2012). This describes an ongoing prospective clinical trial that selects targeted treatment for patients with advanced solid tumours based upon DNA, RNA and microRNA profiling.
Wu, X. et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482, 529–533 (2012).
Tao, Y. et al. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc. Natl Acad. Sci. USA 108, 12042–12047 (2011).
Albiges, L., Gerlinger, M. & PREDICT consortium. The PREDICT (Personalised RNA Interference to Enhance the Delivery of Individualised Cytotoxic and Targeted Therapeutics) approach to biomarker discovery in renal cell carcinoma. Cancer Res. 72, S1746 (2012).
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012). This study demonstrates mutational intratumour heterogeneity within spatially separated regions of the same tumour and matched primary and metastatic lesions separated by time.
Tolmachev, V., Stone-Elander, S. & Orlova, A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol. 11, 992–1000 (2010).
Gasch, C. et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 59, 252–260 (2013).
Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nature Rev. Cancer 11, 426–437 (2011).
Jang, M. H. et al. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res. 14, R115 (2012).
Johnson, C. E. et al. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma. Breast Cancer Res. Treat. 133, 889–898 (2012).
Heselmeyer-Haddad, K. et al. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. Am. J. Pathol. 181, 1807–1822 (2012).
The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Xu, X. et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148, 886–895 (2012).
Hou, Y. et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148, 873–885 (2012).
Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90–94 (2011).
Xu, X. et al. Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing. J. Clin. Oncol. 30, 10516 (2012).
Baselga, J. et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2012).
Turner, N. C. & Reis-Filho, J. S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 13, e178–e185 (2012).
Melcher, C. et al. DETECT III — a multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells. Cancer Res. 72, SOT1–1-10 (2012).
Elisei, R. et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 93, 682–687 (2008).
Park, S. et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J. Thorac. Oncol. 4, 809–815 (2009).
Schmid, K. et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin. Cancer Res. 15, 4554–4560 (2009).
Kim, H. et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J. Thorac. Oncol. 6, 1359–1366 (2011).
Janjigian, Y. Y. et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann. Oncol. 23, 2656–2662 (2012).
Bang, Y.-J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).
Vakiani, E. et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J. Clin. Oncol. 30, 2956–2962 (2012).
Colombino, M. et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30, 2522–2529 (2012).
Antonescu, C. R. et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. 11, 4182–4190 (2005).
Heinrich, M. C. et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 24, 4764–4774 (2006).
Walker, I. et al. Utilizing a collaborative working model to optimize molecular analysis of solid tumors in the Cancer Research UK's stratified medicine programme. J. Clin. Oncol. 31, 11094 (2013).
Rollins, B. et al. PROFILE: Broadly based genomic testing for all patients at a major cancer center. J. Clin. Oncol. 31, 1531 (2013).
Sequist, L. V. et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann. Oncol. 22, 2616–2624 (2011).
MD Anderson Cancer Center. The Sheik Khalifa Bin Zayed Al Nayan Institute for Personalized Cancer Therapy http://www.mdanderson.org/education-and-research/research-at-md-anderson/personalized-advanced-therapy/institute-for-personalized-cancer-therapy/index.html (MD Anderson Cancer Center, 2012).
Mendelson, J. Personalizing oncology: perspectives and prospects. J. Clin. Oncol. 31, 1904–1911 (2013).
Voest, E. Delivering Stratified Medicine: a Strategic Overview. http://www.eacr.org/mpathcourse2012/speaker_presentations.php (EACR, 2012).
Callaway, E. Norway to bring cancer gene tests to the clinic. Nature http://dx.doi.org/10.1038/nature.2012.9949 (2 February, 2012).
Vall d'Hebron Institute of Oncology. Cancer Genomics Group. http://www.vhio.net/research/core-technologies/cancer-genomics-group/en_index.php (Vall d'Hebron Institute of Oncology, 2010).
Vanderbilt-Ingram Cancer Center. Personalized Cancer Therapy at Vanderbilt-Ingram Cancer Center. http://www.vicc.org/personalized (Vanderbilt-Ingram Cancer Center, 2011).
Garraway, L. A. Genomics-Driven Clinical Trials in Oncology: principles and practice. http://www.iom.edu/activities/disease/NCPF/2013-Feb-11.aspx (Institute of Medicine, 2013).
Getz, M. & Boughey, J. Breast Cancer Genome Guided Therapy Study (BEAUTY). http://mayoresearch.mayo.edu/center-for-individualized-medicine/breast-cancer-study.asp (Mayo Clinic, 2012).
Kummar, S. Challenges in Incorporating Integral NGS into Early Clinical Trials. http://cdp.cancer.gov/next-generation_agenda.htm (National Cancer Institute, 2012).
Williams, P. Request for Information (RFI): Efficient Implementation of a Sequencing Network for the Proposed NCI-MATCH Clinical Trial. http://www.fdbdo.com/rfi13-151/ (Fort Detrick Business Development Office, 2013).
Supported in part by the Cancer Care Ontario Applied Cancer Research Units Grant (P.L.B, L.L.S) and by the US National Institute of Health Grant U01 GM61393 (M.J.R).
P.L.B. is a consultant for Roche/Genentech, Novartis and Sanofi, receives research funding (clinical trials) from Roche/Genentech, GlazoSmithKline, Novaris, Sanofi and Servier. M.J.R is a consultant (DSMB chair) for Roche/Genentec, a consultant for Daiichi Sankyo and receives research funding (clinical trial) from Bristol-Myers Squibb. L.L.S receives research funding (clinical trial) from Bristol-Myers Squibb, GlaxoSmithKline, Novartis and Roche/Genentech
Reprints and permissions information is available at www.nature.com/reprints.
About this article
Cite this article
Bedard, P., Hansen, A., Ratain, M. et al. Tumour heterogeneity in the clinic. Nature 501, 355–364 (2013). https://doi.org/10.1038/nature12627
Mass spectrometry imaging of L-[ring-13C6]-labeled phenylalanine and tyrosine kinetics in non-small cell lung carcinoma
Cancer & Metabolism (2021)
CHARTS: a web application for characterizing and comparing tumor subpopulations in publicly available single-cell RNA-seq data sets
BMC Bioinformatics (2021)
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression
British Journal of Cancer (2021)
A multiparametric extraction method for Vn96-isolated plasma extracellular vesicles and cell-free DNA that enables multi-omic profiling
Scientific Reports (2021)
Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway
Nature Communications (2021)